The review found no eligible studies for this question.
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days showed no clear difference in H. pylori persistence, PAN subgroup compared with 7 days (low certainty).
PPI triple therapy for 10 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PANi subgroup compared with 7 days (very low certainty).
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).